Bharat Parenterals profit and loss

Latest FY23

Revenue: ₹218cr+2.8% on FY22
EBITDA: ₹21.4cr−24.1% on FY22
Net profit: ₹24.3cr+14.2% on FY22
EPS: ₹42.14+13.6% on FY22

₹ crore except per share

Tap a line for its trend	FY23Mar 2023	FY22Mar 2022

Expenses
	218	212
	18.8	7.8
	237	220
	146	133
	1.2	1.7
	−9.8	1.7
	16.9	15.3
	2.2	0.9
	5.8	6.7
	42.2	32.5
	205	191
	21.4	28.1
	15.5	21.5
Profit
	32.2	28.4
	8.4	8.3
	−0.6	−0.9
	7.8	7.4
	24.3	21.3
	0.0	−0.2
	24.4	21.1
Per share
	₹42.14	₹37.11
	₹42.14	₹37.11
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	80.5	75.9
	36.9%	35.8%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

BPLPHARMA₹1,912.90

Bharat Parenterals Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersJENBURPH KPL MAKERSL NOVARTIND PARNAXLAB SGRL SHUKRAPHAR SUNLOCMcap ₹1,105 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY22 31/03/2022	FY23 31/03/2023
Revenue from Operations	212.0	218.0
Other Income	7.8	18.8
Total Income	219.8	236.8
Expenses
+ Cost of Materials Consumed	132.7	146.1
+ Purchases of Stock-in-Trade	1.7	1.2
+ Changes in Inventories	1.7	-9.8
+ Employee Benefit Expense	15.3	16.9
+ Finance Costs	0.9	2.2
+ Depreciation & Amortisation	6.7	5.8
+ Other Expenses	32.5	42.2
Total Expenses	191.4	204.7
EBITDA	28.1	21.4
EBIT	21.5	15.5
Profit
Pretax Income	28.4	32.2
+ Current Tax	8.3	8.4
+ Deferred Tax	-0.9	-0.6
Tax Expense	7.4	7.8
Net Income	21.3	24.3
+ Other Comprehensive Income	-0.2	0.0
Total Comprehensive Income	21.1	24.4
Per Share
Basic EPS	37.11	42.14
Diluted EPS	37.11	42.14
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	75.9	80.5
Gross Margin %	35.82	36.93

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY23 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.